
    
      Subjects diagnosed with late stage solid cancer (with or without lung involvement) who failed
      or refused anti-cancer treatment will be enrolled and administered with both: AMOR powder up
      to 1800 mg daily and AMOR Inhaled Double Pack 1% ACC in 8 ml suspension - three times a day.

      Starting Doses:

      1200 mg of AMOR powder (will be administered continuously along the day, each Eppendorf every
      two hours) scaled up by 200 mg every week until maximum dose of 1,800 mg. Patients who will
      not be able to swallow the powder, will receive similar doses of ACC tablets.

      ACC Amor Inhaled Double Pack; 1% ACC in 8 ml suspension - for inhalation three times a day.

      Screening hospital visit:

        -  Inform consent

        -  Subjects' medical charts will be reviewed for medical history, prior cancer treatments

        -  Eligibility Criteria assessment: adherence with inclusion/exclusion criteria

        -  Pathologic diagnosis of cancer and CT/Chest X-Ray will be obtained from the patient's
           charts as needed.

        -  Concomitant medications

        -  Physician evaluation of patient status

        -  Lab: Hematology, Blood chemistry, Albumin Corrected Serum Calcium will be performed
           prior to first dose (blood to be drawn in the morning before breakfast)

        -  Serum 25-hydroxy-vitamin D, i.e. 25(OH)D

        -  Pain VAS score scale

        -  ECOG/Karnofsky performance status

        -  Vital signs (blood pressure and heart rate - supine, respiration rate (RR), oral body
           temperature)

        -  Weight

        -  Oxygen saturation as determined by pulse oximeter/ Dyspnea measurement (Modified Borg
           Scale)

        -  All women of child-bearing potential will have a pregnancy test

        -  Once eligibility criteria are met, subject will undergo CT imaging during screening or
           baseline or week 1 visit.

        -  Following CT, RECIST ver. 1.1 Once eligibility criteria are met, subject will initiate
           treatment of ACC. Vitamin D levels will be re-examined and recorded.

      Baseline (Week 0) hospital visit:

        -  Eligibility Criteria assessment: adherence with inclusion/exclusion criteria

        -  Subjects' medical charts will be reviewed for medical history, prior cancer treatments

        -  Concomitant medications

        -  Lab: Hematology, Blood chemistry, Albumin Corrected Serum Calcium will be performed
           prior to first dose (blood to be drawn in the morning before breakfast; must have
           calcium level measurement before escalation)

        -  Serum 25-hydroxy-vitamin D, i.e. 25(OH)D

        -  VAS once daily

        -  ECOG/Karnofsky performance status

        -  Vital signs (blood pressure and heart rate - supine, respiration rate (RR), oral body
           temperature)

        -  Oxygen saturation as determined by pulse oximeter/ Dyspnea measurement (Modified Borg
           Scale)

        -  All women of child-bearing potential will have a pregnancy test

        -  CT imaging to evaluate tumor size and volume at study initiation, if test was not
           performed between the screening and baseline visit.

        -  RECIST ver. 1.1 (if was not performed during screening visit).

      First ACC Dose:

        -  ACC Per Os (PO) 1200 mg x1 (i.e. 6 AMOR powder Eppendorf's daily, (Amor powder
           administration will be continuous along the day, i.e. each Eppendorf will be
           administered every two hours). Patients who will not be able to swallow the powder, will
           receive similar doses of ACC tablets.

        -  ACC 1% in 8 mL suspension- inhalation for three times a day.

      Week 1 (+/- 2 days range) hospital visit:

        -  Albumin Corrected Serum Calcium will be performed prior to dose escalation (blood to be
           draw in the morning before breakfast)

        -  Dose escalation of ACC PO by 200 mg for a total daily dose of 1400 mg (Amor powder
           administration will be continuous along the day)

        -  ACC 1% in 8 mL suspension- inhalation for three times a day.

        -  Concomitant medications

        -  VAS once daily

        -  Oxygen saturation as determined by pulse oximeter/ Dyspnea measurement (Modified Borg
           Scale)

        -  CT imaging to evaluate tumor size and volume at study initiation, if test was not
           performed during screening visit.

        -  RECIST ver. 1.1 (if was not performed during baseline visit).

        -  AEs/DLTs

      Week 2 (+/- 2 days range) hospital visit:

        -  Albumin Corrected Serum Calcium will be performed prior to dose escalation (blood to be
           draw in the morning before breakfast)

        -  Dose escalation of ACC PO by 200 mg for a total daily dose of 1600 mg (Amor powder
           continuous administration along the day)

        -  ACC 1% in 8 mL suspension- inhalation for three times a day.

        -  Concomitant medications

        -  VAS once daily

        -  Oxygen saturation as determined by pulse oximeter/ Dyspnea measurement (Modified Borg
           Scale)

        -  AEs/DLTs

      Week 3 (+/- 2 days range) hospital visit/ home visit:

        -  Albumin Corrected Serum Calcium will be performed prior to dose escalation (blood to be
           draw in the morning before breakfast)

        -  Dose escalation of ACC PO by 200 mg for a total daily dose 1800 mg (Amor powder
           administration will be continuous along the day)

        -  ACC 1% in 8 mL suspension- inhalation for three times a day.

        -  Concomitant medications

        -  VAS once daily

        -  ECOG/Karnofsky performance status

        -  Oxygen saturation as determined by pulse oximeter/ Dyspnea measurement (Modified Borg
           Scale)

        -  AEs/DLTs

      Treatment Maintenance:

      Week 6 (+/- 2 days range) hospital visit:

        -  ACC PO administration will be continuous along the day at the final patient dosage level

        -  Albumin Corrected Serum Calcium

        -  ACC 1% in 8 mL suspension- inhalation for three times a day.

        -  Concomitant medications

        -  Physician evaluation of patient status

        -  Hematology

        -  Blood chemistry

        -  ECOG/Karnofsky performance status

        -  Pain VAS scale score

        -  Oxygen saturation as determined by pulse oximeter/ Dyspnea measurement (Modified Borg
           Scale)

        -  AEs/DLTs

      Week 12 (+/- 2 days range) hospital visit:

        -  ACC PO administration will be continuous along the day at the final patient dosage level

        -  Albumin Corrected Serum Calcium

        -  ACC 1% in 8 mL suspension- inhalation for three times a day.

        -  Concomitant medications

        -  Physician evaluation of patient status

        -  Hematology

        -  Blood chemistry

        -  CT imaging to evaluate tumor size and volume

        -  RECIST ver. 1.1

        -  ECOG/Karnofsky performance status

        -  Pain VAS scale score

        -  Oxygen saturation as determined by pulse oximeter/ Dyspnea measurement (Modified Borg
           Scale)

        -  AEs/DLTs

      Week 18 (+/- 2 days range) hospital visit:

        -  ACC PO administration will be continuous along the day at the final patient dosage level

        -  Albumin Corrected Serum Calcium

        -  ACC 1% in 8 mL suspension- inhalation for three times a day.

        -  Concomitant medications

        -  Physician evaluation of patient status

        -  Hematology

        -  Blood chemistry

        -  ECOG/Karnofsky performance status

        -  Pain VAS scale score

        -  Oxygen saturation as determined by pulse oximeter/ Dyspnea measurement (Modified Borg
           Scale)

        -  AEs/DLTs

      Week 24 Termination visit (+/- 2 days range) hospital visit:

        -  ACC PO administration will be continuous along the day at the final patient dosage level

        -  Albumin Corrected Serum Calcium

        -  ACC 1% in 8 mL suspension- inhalation for three times a day.

        -  Concomitant medications

        -  Physician evaluation of patient status

        -  Hematology

        -  Blood chemistry

        -  CT imaging to evaluate tumor size and volume at study endpoint

        -  RECIST ver. 1.1

        -  ECOG/Karnofsky performance status

        -  Pain VAS scale score

        -  Oxygen saturation as determined by pulse oximeter/ Dyspnea measurement (Modified Borg
           Scale)

        -  AEs/DLTs A decision regarding a follow up period will be made at the discretion of the
           investigator based on the subject's condition together with subject's agreement. Once
           agree, study drugs will be dispensed for the follow up period. The follow up period will
           be prolonged up to 6 months following study termination.
    
  